Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance

2022 total revenue of $723 million, up 64% from $439 million in 2021 HEPLISAV-B® vaccine net product revenue of $126 million, representing 104% growth compared...

Related Keywords

,Derek Cole ,Ryan Spencer ,Nicole Arndt ,Centers For Disease ,Prevention Advisory Committee Of Immunization Practices ,Delivery Networks Idns ,Dynavax Technologies Corporation Nasdaq ,Exchange Commission ,Development Expenses ,Corporate Communications ,European Union ,Investor Relations Advisory Solutions ,Securities Exchange ,Defense Department Do ,Technologies Corporation ,Chief Executive Officer ,Integrated Delivery Networks ,Adjuvant Supply ,Defense Department ,Administrative Expenses ,Disease Control ,Advisory Committee ,Immunization Practices ,Prescribing Information ,Safety Information ,Securities Act ,Securities Exchange Act ,Annual Report ,Investor Relations ,Dynavax Technologies ,